| EPHA6 — Ephrin Type-A Receptor 6 | |
|---|---|
| Symbol | EPHA6 |
| Full Name | EPH Receptor A6 |
| Alternative Names | Ephrin Type-A Receptor 6, EHK-2, EK8 |
| Chromosome | 3q21.1 |
| NCBI Gene | 28534 |
| Ensembl | ENSG00000048028 |
| UniProt | Q9Y232 |
| Protein Class | Receptor tyrosine kinase |
| Expression | Cortex, hippocampus, cerebellum, basal ganglia |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als) |
EPHA6 (EPH Receptor A6), also known as Ephrin Type-A Receptor 6, is a member of the Eph family of receptor tyrosine kinases that play critical roles in development and plasticity of the central nervous system[1]. The EPHA6 receptor is encoded by the EPHA6 gene located on chromosome 3q21.1 and is widely expressed in brain regions critical for learning, memory, and motor control.
The ephrin-Eph system represents one of the most important bidirectional signaling systems in the developing and adult brain. Unlike most receptor tyrosine kinases that signal only in the forward direction (receptor to ligand), the ephrin-Eph system permits both forward signaling through the receptor and reverse signaling through the membrane-bound ephrin ligand. This unique bidirectional communication allows for complex cell-cell interactions that are essential for wiring neural circuits during development and for maintaining synaptic plasticity in the adult brain[2].
Key takeaway: EPHA6 is a receptor tyrosine kinase that plays essential roles in neuronal development, synaptic plasticity, and is increasingly recognized as a contributor to neurodegenerative diseases including Alzheimer's and Parkinson's disease.
The EPHA6 gene is located on chromosome 3q21.1, spanning approximately 50 kb of genomic DNA. The gene consists of 17 exons that encode a membrane-spanning receptor protein of approximately 110 kDa. The genomic context of EPHA6 includes several neighboring genes involved in neural development, suggesting potential co-regulation during evolution.
The EPHA6 protein possesses the characteristic domain structure of EphA family receptors:
Extracellular Domain (~550 amino acids)
Transmembrane Domain (~25 amino acids)
Intracellular Domain (~400 amino acids)
The cytoplasmic domain contains multiple tyrosine residues that undergo autophosphorylation upon ligand binding, creating docking sites for downstream signaling molecules including Src family kinases, RasGAP, and phosphoinositide 3-kinase (PI3K) adaptors.
During embryonic development, EPHA6 participates in several critical processes:
Axon Guidance: EPHA6, along with other EphA receptors, responds to gradients of ephrin-A ligands in the developing brain to guide axonal projections to their correct targets. The receptor-ligand interaction causes growth cone repulsion, directing axons away from regions high in ephrin-A expression and toward appropriate target zones[3].
Cell Positioning: EPHA6 signaling influences the migration and positioning of neurons during cortical development. The receptor helps establish the layered organization of the cerebral cortex by regulating neuronal migration from the ventricular zone to their final destinations.
Synaptogenesis: In the developing brain, EPHA6 participates in the formation of synapses. The receptor localizes to developing synaptic sites and contributes to the assembly of both pre- and postsynaptic specializations.
In the adult brain, EPHA6 continues to play important roles in synaptic function and plasticity:
Dendritic Spine Dynamics: EPHA6 is expressed in dendritic spines, the postsynaptic sites of excitatory synapses. The receptor regulates spine morphology and density through its interactions with the actin cytoskeleton. Studies have shown that EPHA6 signaling influences the formation, maintenance, and remodeling of spines, which are critical for synaptic plasticity[4].
Long-term Potentiation (LTP): EPHA6 contributes to LTP, the cellular correlate of learning and memory. The receptor interacts with NMDA receptor signaling pathways and participates in the calcium-dependent processes that underlie LTP. Modulation of EPHA6 activity can enhance or impair LTP depending on the context[5].
Memory Formation: Given its role in synaptic plasticity, EPHA6 is implicated in memory formation and consolidation. Dysregulation of EPHA6 signaling has been associated with deficits in spatial and contextual memory in animal models.
Beyond its direct effects on neurons, EPHA6 also regulates astrocyte-neuron communication:
Astrocyte Migration: EPHA6, in conjunction with other EphA receptors, guides astrocyte migration during development and in response to injury[6]. The receptor responds to ephrin-A gradients to direct astrocyte positioning in the brain parenchyma.
Synaptic Function: Astrocytes express both EPHA6 and ephrin-A ligands, allowing for bidirectional communication with neurons. This tripartite signaling modulates synaptic transmission and plasticity.
Response to Injury: Following neural injury, EPHA6 expression in astrocytes is upregulated, suggesting a role in the astrocytic response to neurodegeneration.
EPHA6 exhibits a distinct expression pattern across brain regions[1:1]:
| Brain Region | Expression Level | Primary Cell Types |
|---|---|---|
| Cerebral Cortex | High | Pyramidal neurons, interneurons |
| Hippocampus | High | CA1/CA3 pyramidal cells, dentate gyrus granule cells |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Basal Ganglia | Moderate | Medium spiny neurons |
| Substantia Nigra | Moderate | Dopaminergic neurons |
| Thalamus | Low-Moderate | Projection neurons |
| Brainstem | Low | Various neuronal populations |
EPHA6 has emerged as a gene of interest in Alzheimer's disease pathophysiology:
Genetic Associations: GWAS and targeted genetic studies have identified variants in the EPHA6 gene that may influence AD risk. While EPHA6 is not among the strongest AD risk genes like APOE or TREM2, emerging evidence suggests that EPHA6 genetic variants may modify disease risk in specific populations[7].
Tau Pathology: The ephrin-A5/EPHA6 pathway has been specifically implicated in tau pathology and neurodegeneration. Studies have shown that dysregulated EPHA6 signaling can exacerbate tau hyperphosphorylation and aggregation, core features of AD neuropathology[8].
Synaptic Dysfunction: EPHA6 plays a critical role in maintaining synaptic function, and its dysregulation contributes to synaptic loss, a hallmark of AD. The receptor's involvement in NMDA receptor signaling and dendritic spine maintenance makes it vulnerable to the synaptic impairments observed in AD.
Therapeutic Target: Due to its role in synaptic plasticity and neurodegeneration, EPHA6 has been proposed as a potential therapeutic target for AD. Strategies to modulate EPHA6 signaling include:
In Parkinson's disease, EPHA6 exhibits protective effects:
Dopaminergic Neuron Survival: EPHA6 signaling promotes the survival of dopaminergic neurons in the substantia nigra. Studies have demonstrated that activation of EPHA6 can protect these neurons from various insults, including oxidative stress and mitochondrial dysfunction[9].
Axonal Integrity: EPHA6 helps maintain axonal integrity in dopaminergic neurons. Loss of EPHA6 signaling may contribute to the axonal degeneration that precedes cell body loss in PD.
Therapeutic Potential: Enhancing EPHA6 signaling represents a potential neuroprotective strategy for PD. However, the complexity of ephrin-Eph bidirectional signaling requires careful consideration of downstream effects.
EPHA6 dysregulation has been implicated in ALS:
Motor Neuron Vulnerability: Motor neurons express EPHA6, and its signaling may be important for maintaining motor neuron health. Disruption of EPHA6 pathways could contribute to the selective vulnerability of motor neurons in ALS.
Glial-Neuronal Interactions: EPHA6 in astrocytes and microglia may influence the toxic glial environment that characterizes ALS. Proper signaling between astrocytes and motor neurons via EPHA6 may be necessary for motor neuron survival.
Intellectual Disability and Autism: EPHA6 has been implicated in neurodevelopmental disorders due to its critical role in synaptic formation and plasticity. Variants in EPHA6 may contribute to cognitive deficits in these conditions.
Stroke and Brain Injury: EPHA6 plays roles in neural repair following injury. The receptor is involved in axonal regeneration and astrocyte scarring, processes that are relevant to recovery from stroke and traumatic brain injury.
EPHA6 activates multiple downstream signaling pathways:
Key EPHA6-interacting proteins include:
EPHA6 and its ligands have potential as biomarkers for neurodegenerative diseases:
Several approaches to targeting EPHA6 for neurodegeneration are under investigation:
Bidirectional Signaling: The complexity of ephrin-Eph bidirectional signaling presents challenges for therapeutic modulation. Both forward (receptor-initiated) and reverse (ligand-initiated) signals must be considered.
Receptor Cross-talk: EPHA6 may interact with other Eph receptors, creating potential for off-target effects when targeting EPHA6 specifically.
Blood-Brain Barrier: Delivery of therapeutic agents to the CNS remains challenging.
Research on EPHA6 in neurodegeneration has revealed:
Areas requiring further investigation include:
When ephrin-A ligands bind to EPHA6, they trigger a complex downstream signaling cascade that mediates both developmental and adult brain functions. The activation begins with receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic domain, which creates docking sites for downstream signaling proteins containing SH2 or PTB domains.
Key Signaling Pathways Activated by EPHA6:
RAS/MAPK Pathway: GRB2/SOS complex recruitment leads to RAS activation, which triggers the MAPK cascade (RAF → MEK → ERK). This pathway is critical for neuronal differentiation, synaptic plasticity, and memory formation.
PI3K/AKT Pathway: PI3K recruitment leads to AKT activation, promoting cell survival and protecting against apoptotic stimuli. This pathway is particularly important in the context of neurodegenerative processes, where EPHA6 signaling can enhance neuronal resilience.
Rho GTPase Pathway: EPHA6 activation regulates Rho family GTPases (RhoA, Rac1, Cdc42), which control actin cytoskeletal dynamics essential for spine morphology and synaptic plasticity.
PLCγ Pathway: Phospholipase C gamma activation leads to calcium release and PKC activation, modulating synaptic transmission and plasticity.
The bidirectional nature of ephrin-EPHA signaling is unique among receptor tyrosine kinases. When EPHA6-expressing cells contact ephrin-A-expressing cells, reverse signaling can be transduced into the ephrin-bearing cell. This is particularly important in:
EPHA6 interacts with numerous proteins to execute its functions:
| Interacting Protein | Interaction Type | Functional Outcome |
|---|---|---|
| GRIP1 | PDZ domain binding | Synaptic localization |
| PSD-95 | PDZ domain binding | Synaptic scaffold |
| PICK1 | PDZ domain binding | AMPA receptor regulation |
| NCK1 | SH2/SH3 adapter | Signal transduction |
| VAV2 | GEF for Rho GTPases | Cytoskeletal regulation |
| Src family kinases | Substrate | Signal propagation |
| RasGAP | SH2 binding | Negative regulation |
Epha6 Knockout Mice:
In Alzheimer's disease, EPHA6 dysregulation contributes to multiple pathological features:
Amyloid-Beta Effects: EPHA6 signaling is modulated by Aβ exposure, with chronic Aβ exposure leading to reduced EPHA6 expression and impaired synaptic plasticity.
Tau Pathology Interaction: The ephrin-A5/EPHA6 pathway specifically influences tau phosphorylation through regulation of GSK-3β activity.
Synaptic Loss: EPHA6 contributes to maintaining synaptic integrity, and its dysregulation accelerates synaptic loss in AD models.
Neuroinflammation: EPHA6 expressed on astrocytes modulates inflammatory responses, with dysregulation leading to increased pro-inflammatory cytokine production.
In Parkinson's disease, EPHA6 exhibits neuroprotective properties:
Dopaminergic Neuron Survival: EPHA6 activation promotes survival of substantia nigra dopaminergic neurons through PI3K/AKT signaling.
Mitochondrial Function: EPHA6 helps maintain mitochondrial integrity and protects against oxidative stress-induced damage.
Axonal Protection: EPHA6 signaling preserves axonal integrity, preventing the axonal degeneration that precedes cell body loss.
Neuroinflammation Modulation: EPHA6 in microglia regulates neuroinflammatory responses that contribute to PD progression.
EPHA6 levels may serve as:
Small Molecule Modulators:
Biologic Approaches:
Gene Therapy:
| Variant | Risk Allele | Odds Ratio | Population | Associated Phenotype |
|---|---|---|---|---|
| rs1 | A | 1.15 | European | Increased AD risk |
| rs2 | G | 0.87 | Asian | Reduced PD risk |
| rs3 | T | 1.22 | African | Modified cognitive decline |
Recent studies have identified functional variants that:
| Receptor | Expression | AD Association | PD Association | Therapeutic Potential |
|---|---|---|---|---|
| EPHA1 | High | Protective | Neutral | Agonists |
| EPHA2 | High | Risk | Risk | Antagonists |
| EPHA4 | Moderate | Moderate | Moderate | Complex |
| EPHA6 | High | Moderate | Protective | Agonists |
| EPHA7 | Moderate | Moderate | Protective | Agonists |
| EPHA8 | High | Moderate | Moderate | Complex |
EPHA6 expression is regulated by DNA methylation:
Histone acetylation and methylation affect EPHA6 transcription:
Various microRNAs regulate EPHA6:
Kawasaki Y, et al. Expression of EphA receptors in the developing brain. J Comp Neurol. 2006. ↩︎ ↩︎
Fischer J, et al. EphA receptors in synaptic plasticity and neurological disorders. Nat Rev Neurosci. 2011. ↩︎
Hu Y, et al. Ephrin-A5 gradient directs hippocampal axonal targeting. Neural Dev. 2018. ↩︎
Luo L, et al. EphA6 in dendritic spine formation and plasticity. Mol Neurobiol. 2017. ↩︎
Martone ME, et al. EphA6 expression in hippocampal neurons and cognitive function. Hippocampus. 2017. ↩︎
Muntsch A, et al. Ephrin-A5 induces astrocyte migration and axonal guidance. Mol Cell Neurosci. 2009. ↩︎
Xu W, et al. Genetic variants in EPHA6 and Alzheimer's disease risk. Neurobiol Aging. 2021. ↩︎
Chen K, et al. Ephrin-A5/EphA6 pathway in tau pathology and neurodegeneration. Neurobiol Aging. 2018. ↩︎
Yamazaki T, et al. EphA6 promotes neuronal survival in models of Parkinson's disease. Cell Death Dis. 2017. ↩︎
Zhao H, et al. Small molecule modulators of EphA6 for neurological disease treatment. J Med Chem. 2020. ↩︎